MedTrace Logo

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

NCT06435858 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-12

No results posted yet for this study

Summary

This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.

Patients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.

Conditions

  • Autosomal Dominant Polycystic Kidney Disease

Interventions

DRUG

Empagliflozin

Empagliflozin 10mg

DRUG

Placebo

Placebo capsule

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • Cantonal Hospital Graubuenden

    lead OTHER

Principal Investigators

  • Thomas Fehr, MD · Cantonal Hospital Graubuenden

  • Patrick Hofmann, MD · Cantonal Hospital Graubuenden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-07-01
Completion
2025-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06435858 on ClinicalTrials.gov